References
- Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, Bathon JM. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55(2):333–7.
- Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004;25(5):331–5.
- Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689–95.
- Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, Dougados M. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25(3):430–6.
- Yurbe T, Takahi K, Ozaki H, Fuji T, Kurosaka M, Doita M. Late infection of total knee arthroplasty inflamed by anti-TNFα, Infliximab therapy in rheumatoid arthritis. Rheumatol Int. 2010;30(3):405–8.
- Guidelines of TNF inhibition therapy for rheumatoid arthritis (RA) (2012 revised edition). Japan College of Rheumatology.
- Adalimumab treatment guidelines for rheumatoid arthritis (RA). Japan College of Rheumatology.
- Tocilizumab treatment guidelines for rheumatoid arthritis (RA) (2012 revised edition). Japan College of Rheumatology.
- Abatacept treatment guidelines for rheumatoid arthritis (RA). Japan College of Rheumatology.
- Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20(4):250–78.
- Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93.
- Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use, risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1157–60.
- Grennan DM, Gray J, Loudon J, Fear S. Methotrexate early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001; 60(3):214–7.
- Jain A, Witbreuk M, Ball C, Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and surgery. J Hand Surg Am. 2002;27(3):449–55.
- Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21(5):469–75.
- Kubota A, Nakamura T, Miyazaki Y, Sekiguchi M, Suguro T. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol. 2012;22(6):844–8.
- Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009;68(5):654–7.
- Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol. 2013;23(3):440–9.